• Artículo
      Icon

      Vedolizumab response in inflammatory bowel disease. Two years of follow-up 

      Belvis Jiménez, María Inmaculada; Pino Bellido, Pilar del; Castro Laria, Luisa; Maldonado Pérez, María Belén; Sáez Díaz, Antonia; Caunedo Álvarez, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2020)
      Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and ...